Curcuminoid Composition BDMC Curcumin Ratio Bioavailability

The patent changes the compositional parameters by reducing curcumin content from conventional high levels (70-75% w/w) to a specific range (5-20% w/w), and simultaneously increases BDMC content to a specific range (65-80% w/w). This parameter transformation resolves the contradiction by creating a composition where the enhanced stability and bioavailability of BDMC compensates for the reduced curcumin content, while the synergistic interaction between curcumin and BDMC maintains therapeutic efficacy.

The patent creates a composite curcuminoid composition where BDMC serves as the primary component (65-80% w/w) and curcumin is present as a secondary component (5-20% w/w). This composite structure leverages the superior chemical stability of BDMC to protect and enhance the overall stability of the formulation, while the synergistic interaction between the two curcuminoids maintains the desired pharmacological effects. The composite approach transforms the instability of high-curcumin formulations into a stable, effective composition.